An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Issue 9 (2nd September 2019)

• Record Type: Journal Article
• Authors: Piccinin, Carolyn; Panchal, Seema; Watkins, Nicholas; Kim, Raymond H
• Is Part Of: Expert review of anticancer therapy. Volume 19:Issue 9(2019)
• Page Start: 787
• Page End: 801
• Publication Date: 2019-09-02
• Subjects: Gene panel testing -- hereditary breast cancer -- breast cancer -- next generation sequencing -- moderate risk genes -- germline testing -- tumor testing -- models of delivery in genetic testing; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2019.1659730
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : In the past 5 years, multi-gene panels have replaced the practice of BRCA1 and BRCA2 genetic testing in cases of suspected inherited breast cancer susceptibility. A variety of genes have been included on these panels without certainty of their clinical utility. Pertinent current and historical literature was reviewed to provide an up-to-date snapshot of the changing landscape of the use of gene panel tests in the context of breast cancer. Areas covered : Following a recent review of the evidence, 10 genes have been found to have definitive evidence of increased breast cancer risk with variable penetrance. Here, we review the recent changes to the practice of multi-gene panel use in breast cancer diagnoses, including an update on next generation sequencing, alternative models of genetic testing, considerations when ordering these panel tests, and recommendations for management in identified carriers for a variety of genes. A comparison of screening recommendations and carrier frequencies from recent studies is also explored. Lastly, we consider what the future of hereditary oncologic genetic testing holds. Expert opinion : The transition to multi-gene panels in breast cancer patients has improved the likelihood of capturing a rare variant in a well-established gene associated with hereditary breast cancer (e.g. BRCA1 and BRCA2, TP53 ). There is also an increase in the likelihood of uncovering an uncertain result. This could be in the form of a variant of uncertain significance, or a pathogenic variant in a gene with questionable breast cancer risk-association. Concurrently, a changing landscape of who orders genetic tests will improve access to genetic testing. This pervasiveness of genetic testing must be accompanied with increased genetic literacy in all health-care providers, and access to support from genetics professionals for management of patients and at-risk family members.